CTLA4 and lung cancer: CTLA‐4 inhibitor ipilimumab alone showed no significant effect on lung cancer [21]. Neoadjuvant immunotherapy in patients with resectable NSCLC resulted in a 45% major pathology response (MPR) and 40% downstaging.